Pattern Separation in Major Depressive Disorder
Study Details
Design, interventions, and primary outcomes
About This Study
This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on neuropsychological function, regional brain activity assessed by functional magnetic resonance imaging, and depressive symptoms, in participants with Major Depressive Disorder. Escitalopram is administered in an open-label fashion in this study; extended release memantine is administered in a double-blind, randomized, placebo-controlled manner.
Design
Interventions / Regimen
- Drug: SSRI (escitalopram or sertraline) — 11 weeks of open-label treatment with an SSRI, of which the last 6 weeks are augmented with memantine vs placebo. Primary SSRI for the study is escitalopram. In cases of prior intolerance or non-response to escitalopram, individuals will be treated with sertraline instead of escitalopram.
- Drug: Extended-Release Memantine — 6 weeks of treatment with extended-release memantine as augmentation to ongoing escitalopram treatment
- Drug: Placebo — 6 weeks of treatment with placebo as augmentation to ongoing escitalopram treatment
Primary Outcomes
- Pattern Separation Performance (At baseline (week 0) and after completing the medication trial (week 11))
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06-01
Completion: 2027-06-30
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
- Jeffrey M Miller, MD (PRINCIPAL_INVESTIGATOR) - New York State Psychiatric Institute (NYSPI)
- Drug: SSRI (escitalopram or sertraline) — 11 weeks of open-label treatment with an SSRI, of which the last 6 weeks are augmented with memantine vs placebo. Primary SSRI for the study is escitalopram. In cases of prior intolerance or non-response to escitalopram, individuals will be treated with sertraline instead of escitalopram.
- Drug: Extended-Release Memantine — 6 weeks of treatment with extended-release memantine as augmentation to ongoing escitalopram treatment
- Drug: Placebo — 6 weeks of treatment with placebo as augmentation to ongoing escitalopram treatment